Haynes Boone Advises on Signing of Pulmatrix Merger Agreement with Eos and Concurrent $19 Million Financing
Haynes Boone advised on the announced signing of the merger agreement between Pulmatrix, Inc. (Nasdaq: PULM) and Eos SENOLYTIX, Inc., a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases. Haynes Boone also advised on a concurrent private financing of PULM in connection with the merger.